🟢 Neurosense Therapeutics Ltd is trading 5.3% up today after securing a new patent in South Korea for its ALS drug candidate

Neurosense Therapeutics Ltd is trading 5.3% up at $0.77 in pre-market after the company announced it has been granted a patent in South Korea for its lead ALS drug candidate, PrimeC.

• The new patent covers PrimeC's composition, manufacturing process, and use for treating ALS, with protection expected through 2042.
• This announcement follows a similar patent grant in Japan on June 9, which continues to bolster the company's global intellectual property portfolio.
• The stock is reacting positively to the continued expansion of patent protection for its lead drug candidate as NeuroSense prepares to initiate Phase 3 development.